# Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Canonical URL: https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-distribution-and-licensing-agreement-with-dr-reddy-s-for-xacduror-in-select-international-markets
Ticker: INVA
Company: Innoviva
Source: Innoviva
Published: 2026-06-25 13:46 EST
Original Source URL: https://investor.inva.com
## Summary

Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals) The rate of carbapenem resistant

## Article Body
Agreement expands access to XACDURO ® for patients with serious Acinetobacter baumannii-calcoaceticus complex (Acinetobacter) infections across South and Central America, the Caribbean, Russia and CIS countries (following applicable regional regulatory approvals) The rate of carbapenem resistant
## Recent Company News
- 2026-06-25 13:46 EST — [Nortiva Bio Launches to Develop Long-Acting Oral Medicines](https://biopharmsignal.com/news/INVA/nortiva-bio-launches-to-develop-long-acting-oral-medicines) — Source: Innoviva
- 2026-06-25 13:46 EST — [Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets](https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-announces-distribution-and-licensing-agreement-with-dr-reddy-s-for-xacduror-in-select-international-markets) — Source: Innoviva
- 2026-06-25 13:46 EST — [Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress](https://biopharmsignal.com/news/INVA/innoviva-reports-first-quarter-2026-financial-results-highlights-recent-company-progress) — Source: Innoviva
- 2026-06-25 13:46 EST — [Innoviva Specialty Therapeutics’ Antimicrobial Therapies ZEVTERA® and XACDURO® Nominated for the 2025 Prix Galien USA Best Pharmaceutical Product Award](https://biopharmsignal.com/news/INVA/innoviva-specialty-therapeutics-antimicrobial-therapies-zevterar-and-xacduror-nominated-for-the-2025-prix-galien-usa-best-pharmaceutical-product-award) — Source: Innoviva
- 2026-06-25 13:46 EST — [Innoviva to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/INVA/innoviva-to-participate-in-upcoming-investor-conferences) — Source: Innoviva
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)